Today: 19 May 2026
Browse Category

NASDAQ:ADAP 19 August 2025 - 16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune shares jumped 52% on October 8, 2025, amid heavy speculative trading, but remain down about 75% year-over-year and trade near $0.20. The company sold its main T-cell therapy programs to US WorldMeds for $55 million upfront, cleared its debt, and now faces “substantial doubt” about its ability to continue. Analysts rate the stock as high risk, with no major firm recommending a Buy.
9 October 2025
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • TSX Penny Stocks To Watch In May 2026: Neptune Digital Assets, Orecap Invest
    May 19, 2026, 3:25 PM EDT. The Canadian TSX market shows resilience in 2026, aided by strong sectors like energy and technology. Penny stocks, small-cap or newer firms trading at low prices, attract investors seeking growth potential backed by solid financials. Neptune Digital Assets (market cap CA$120.58 million) reported mixed Q2 results with net income of CA$2.16 million despite falling sales, maintaining financial stability through cash reserves and diversifying into gold and silver tokens. Orecap Invest Corp. (market cap CA$33.53 million) posted CA$6.18 million net income in Q1 2026 while remaining pre-revenue, sustaining financial health with no debt and experienced management, despite auditor concerns. Both firms highlight the nuanced investment opportunities within the TSX penny stock realm amid ongoing market uncertainties.

Latest articles

DFW Flight Cancellations Surge Past 350 As Storms Hit American Airlines’ Biggest Hub

DFW Flight Cancellations Surge Past 350 As Storms Hit American Airlines’ Biggest Hub

19 May 2026
Dallas, May 19, 2026, 14:11 CDT Cancellations at Dallas-Fort Worth International Airport climbed to 359 on Tuesday after thunderstorms forced a ground stop, an air-traffic order that holds flights at their origin to keep congestion from building over an airport. FlightAware data also showed 452 delays at DFW by early afternoon. (FlightAware) The timing is awkward for American Airlines. DFW is the carrier’s largest and most important hub, with more customers and bags connecting there each day than at any other airport in its network, American said in December. The airline said more than 30% of its daily connecting customers
Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

19 May 2026
Marvell shares climbed 6.6% to $180.04 Tuesday, outperforming a falling Nasdaq as investors positioned ahead of its May 27 earnings call. Trading volume reached 15.3 million shares, with the company’s market value near $155.5 billion. The stock’s rally followed analyst price target hikes and speculation over AI data-center demand. Marvell last reported record annual revenue and forecast further growth led by its data-center business.
Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

19 May 2026
Enbridge Inc. shares hit a 52-week high of C$78.25 on Tuesday, rising 2.76% even as the S&P/TSX Composite slipped 0.1% amid inflation concerns. The move came after the company reaffirmed 2026 financial guidance and despite a partial construction pause on its Line 5 project in Wisconsin. Pembina Pipeline shares also rose, though less sharply.
Go toTop